Merus (MRUS) News Today $94.70 +0.26 (+0.28%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.October 21 at 8:12 AM | globenewswire.comTD Asset Management Inc Acquires 17,852 Shares of Merus N.V. $MRUSOctober 21 at 3:45 AM | marketbeat.comMerus (NASDAQ:MRUS) Hits New 1-Year High - What's Next?October 18 at 5:40 PM | marketbeat.comMerus N.V. $MRUS Shares Sold by Aberdeen Group plcOctober 17, 2025 | marketbeat.comMerus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...October 14, 2025 | markets.businessinsider.comMerus announces initial interim data from phase 2 trial of petosemtamabOctober 14, 2025 | msn.comMerus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14, 2025 | globenewswire.comMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular ...October 13, 2025 | markets.businessinsider.comMerus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in BostonOctober 13, 2025 | quiverquant.comQMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 13, 2025 | globenewswire.comMerus (MRUS): Assessing Valuation After Rapid Share Price GainsOctober 11, 2025 | finance.yahoo.comMerus (NASDAQ:MRUS) Hits New 12-Month High - Here's WhyOctober 10, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold"October 7, 2025 | marketbeat.comLeerink Partners Downgrades Merus N.V. (MRUS)October 6, 2025 | msn.comMerus Sees Unusually Large Options Volume (NASDAQ:MRUS)October 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Merus FY2027 Earnings?October 2, 2025 | marketbeat.comPlatinum Investment Management Ltd. Lowers Holdings in Merus N.V. $MRUSOctober 2, 2025 | marketbeat.comMerus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth PotentialOctober 2, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of ShareholdersOctober 1, 2025 | globenewswire.comWhat is William Blair's Estimate for Merus FY2027 Earnings?October 1, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Rating Lowered to "Hold" at Lifesci CapitalOctober 1, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Downgraded by Guggenheim to HoldOctober 1, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Cut to "Hold" at BarclaysOctober 1, 2025 | marketbeat.comAvior Wealth Management LLC Makes New Investment in Merus N.V. $MRUSOctober 1, 2025 | marketbeat.comMERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUSSeptember 30, 2025 | businesswire.comLifeSci Capital Downgrades Merus N.V. (MRUS)September 30, 2025 | msn.comMerus (MRUS) Soars to New High on Genmab Merger at 41% PremiumSeptember 30, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)September 30, 2025 | prnewswire.comMerus (NASDAQ:MRUS) Sees Large Volume Increase - Here's WhySeptember 30, 2025 | marketbeat.comMerus' (MRUS) Neutral Rating Reiterated at GuggenheimSeptember 30, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci CapitalSeptember 30, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & CompanySeptember 30, 2025 | marketbeat.comWells Fargo Downgrades Merus N.V. (MRUS)September 30, 2025 | msn.comEQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transactionSeptember 30, 2025 | finance.yahoo.comMerus downgraded to Market Perform from Outperform at LifeSci CapitalSeptember 29, 2025 | msn.comMerus downgraded to Neutral from Buy at H.C. WainwrightSeptember 29, 2025 | msn.comExpert Outlook: Merus Through The Eyes Of 4 AnalystsSeptember 29, 2025 | benzinga.comMid Cap Stocks To Consider - September 29thSeptember 29, 2025 | marketbeat.comPromising Medical Stocks To Keep An Eye On - September 29thSeptember 29, 2025 | marketbeat.comGenmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into RevenueSeptember 29, 2025 | seekingalpha.comMerus (NASDAQ:MRUS) Hits New 12-Month High - Time to Buy?September 29, 2025 | marketbeat.comGenmab Makes $8 Billion Bet On Merus With Potential Cancer BreakthroughSeptember 29, 2025 | benzinga.comMerus (NASDAQ:MRUS) Receives Neutral Rating from CitigroupSeptember 29, 2025 | marketbeat.comMRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to ShareholdersSeptember 29, 2025 | businesswire.comGenmab to Acquire Merus, Expanding Pipeline and Strategic GrowthSeptember 29, 2025 | tipranks.comGenmab in advanced talks to buy Dutch drugmaker Merus - BloombergSeptember 29, 2025 | in.investing.comGenmab near deal to acquire Merus, Bloomberg saysSeptember 29, 2025 | msn.comMerus N.V. (NASDAQ:MRUS) Given Average Rating of "Buy" by AnalystsSeptember 29, 2025 | marketbeat.comGenmab to buy Dutch cancer drugmaker Merus for $8 billionSeptember 29, 2025 | reuters.com Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRUS Media Mentions By Week MRUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼-0.190.50▲Average Medical News Sentiment MRUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼78▲MRUS Articles Average Week Get the Latest News and Ratings for MRUS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Merus and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BioNTech News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Summit Therapeutics News Today Ascendis Pharma A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Roivant Sciences News Today BridgeBio Pharma News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts